Los Angeles, CA, United States of America

Mark Amin Aminzadeh

This inventor holds 3 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignees: Cedars-Sinai Medical Center, Capricor, Inc.. Active years: 2022-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mark Amin Aminzadeh. Retrieved from https://idiyas.com/inventor/mark-amin-aminzadeh

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 3 

% Patents Active = 100.0


 

Average Co-Inventor Count = 2.6

ph-index = 2

Forward Citations = 8(Granted Patents)


Company Filing History:


Years Active: 2022-2026

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Mark Amin Aminzadeh: Innovator in Cardiosphere-Derived Cell Therapies

Introduction

Mark Amin Aminzadeh is a prominent inventor based in Los Angeles, CA. He has made significant contributions to the field of regenerative medicine, particularly in the treatment of muscular dystrophy. With a total of 3 patents, his work focuses on the therapeutic applications of cardiosphere-derived cells and their exosomes.

Latest Patents

Aminzadeh's latest patents include groundbreaking research on cardiosphere-derived cells and exosomes secreted by these cells in the treatment of muscular dystrophy. His first patent describes compositions and techniques related to the generation and therapeutic application of cardiosphere-derived cells (CDCs) and CDC-derived exosomes. These cells and their secreted vesicles contain a unique milieu of biological factors, including cytokines, growth factors, transcription factors, and nucleic acids, such as microRNAs. These components serve to initiate and promote various therapeutic effects. The exosomes and their cargo can favorably modulate apoptosis, inflammation, and fibrosis in the injured heart, making CDC-derived exosomes a novel “cell-free” therapeutic candidate for tissue repair.

Another patent outlines methods and compositions for treating skeletal muscular dystrophy. This includes a method of treating Duchenne muscular dystrophy (DMD) with cardiosphere-derived cells, wherein a therapeutically effective amount of CDCs is delivered to targeted dystrophic skeletal muscle. The patent also discusses the delivery of CDCs via intramuscular injection or systemic administration, either in a single dose or multiple doses. Additionally, it highlights the potential for improving exercise capabilities in DMD patients through exosome-mediated transfer of noncoding RNAs, which can restore dystrophin in heart and skeletal muscle.

Career Highlights

Throughout his career, Mark Amin Aminzadeh has worked with esteemed institutions such as Cedars-Sinai Medical Center and Capricor, Inc. His innovative research has positioned him as a leader in the field of regenerative medicine.

Collaborations

Aminzadeh has collaborated with notable professionals in his field, including Eduardo Marban and Luis Rodriguez-Borlado. Their combined expertise has contributed to the advancement of therapeutic strategies for muscular dystrophy.

Conclusion

Mark Amin Aminzadeh is a distinguished inventor whose work in cardiosphere-derived

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…